A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Early Phase 1

Not yet recruiting

• Conditions: Solid Tumor
• Interventions: Biological: LM103

• Registration Number: NCT05971576
• Lead Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.

Brief Summary

This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients . The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-06
• Study First Submitted: 2023-07-12
• Study First Submitted QC: 2023-07-25
• Last Update Submitted: 2023-07-25
• Study Start: 2023-08
• Study First Posted: 2023-08-02
• Last Update Posted: 2023-08-02
• Primary Completion: 2026-04
• Study Completion: 2026-08

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. The expected survival time is not less than 3 months.
2. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0-1.
3. Patients with advanced solid tumors confirmed by histology or cytology: advanced Melanoma, cervical cancer/ovarian cancer, head and neck squamous cell cancer, non-small cell lung cancer, esophageal cancer and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available.
4. The patient has lesions that can be used for surgical resection (>1.5 cm3) or biopsy puncture (no less than 6 lesions) for TILs collection.
5. At least one measurable lesion as the target lesion after collecting tumor tissue from the patient (RECIST v1.1 criteria).
6. Laboratory tests results during the screening period indicate that the subjects have sufficient organ function.

Exclusion Criteria

1. Have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical Carcinoma in situ, basal or squamous cell skin cancer or Ductal carcinoma in situ of the breast treated by radical surgery).
2. LM103 received systematic Sex therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, Hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis>3 weeks before the start of the study were acceptable) within 4 weeks before LM103 infusion; Or received clinical investigational drugs or equipment treatment.
3. Adverse reactions caused by previous treatment have not recovered to CTCAE (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time).
4. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Intravenous of LM103	LM103	≥5×10\^9 cells (LM103) will be infused i.v. to patients after non-myeloablative lymphodepletion treatment with Cyclophosphamide for Injection and Fludarabine Phosphate for Injection.

Primary Outcome Measures

Name	Time	Method
Adverse events (AE), Serious adverse event (SAE) and immune related adverse events (irAE)	through study completion, an average of 1 year estimate	Incidence and severity of AE, SAE and irAE; Abnormal changes in laboratory and other tests with clinical significance.

Secondary Outcome Measures

Name	Time	Method
Objective response rate (ORR)	through study completion, an average of 1 year estimate	The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment based on RECIST version 1.1.
Progression free survival (PFS)	through study completion, an average of 1 year estimate	Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST version 1.1) or death due to any cause.
Disease control rate (DCR)	through study completion, an average of 1 year estimate	Disease control rate (DCR) was defined as the percentage of participants with a best overall response of complete response, partial response or stable disease as defined by RECIST version 1.1.
Time to response (TTR)	through study completion, an average of 1 year estimate	Time to response (TTR) is defined as the time from randomization until the first documented evidence of CR or PR.
Duration of response (DOR)	through study completion, an average of 1 year estimate	Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause.
Overall survival (OS)	through study completion, an average of 1 year estimate	OS was defined as the time from first dose to date of death from any cause.
Time to disease progression (TTP)	through study completion, an average of 1 year estimate	Time to progression (TTP) is defined as the interval between the date of randomization and the earliest date of progression of disease (PD) or death due to the solid tumor.
Peripheral blood TILs cell survival	through study completion, an average of 1 year estimate	Detection using flow cytometry